

# **BIOBANKING**

# The Karolinska Institutet Experience

Per Hall, professor, senior consultant

Department of Medical Epidemiology and Biostatistics

Karolinska Institutet


Department of Oncology, Södersjukhuset

Stockholm, Sweden

# Overview of my talk

- Karolinska Biobank today
- The Karma Intervention Study
- Karolinska Biobank tomorrow

Karolinska Biobank - today



#### Some statistics

• Number of doners:  $\approx$  750,000 (7.5% of the Swedish population)

Number of samples: ≈ 8,000,000

Number of papers: 227 (since 2011 from our group only)

Number of sample types
 56 (e.g. DNA, plasma, hair, breast milk, umbillicord

blood, bone marrow)

Number of tube types:

Sample withdrawals:

→ 2020-2022 ≈ 70 000 samples/year

# Storage

Static storage

Room temperature filter paper

o +4°C saliva

o -20°C DNA

o -80°C plasma, serum


o -196°C liquid nitrogen viable cells

Automated storage: Auto freezer (-80°C)



# What is biobanking?

- Three important dimensions;
  - **→** Regulatory
  - → Data / IT
  - **→** Laboratory
- In order to, in a legally and ethically correct way;
  - → Handle and prepare human samples
  - → Secure storage of samples
  - → Guarantee traceability of samples
  - → Send samples for analysis



## What is biobanking?

#### Regulatory aspects

- → Adherence to biobank laws and regulations
- → Applications to authorities such as the Medical Products Agency and the Ethical Board
- → Biobank agreements
- → Sample agreements
  - Material transfer agreement (MTA)
  - Data transfer agreement (DTA)
  - Data processing agreement (DPA)

#### Data / IT

→ Laboratory information management system (LIMS)

8

- Traceability
- Data filtering and visualisation
- Automation
- → Referral
- → Databases
- → Integrations

#### Lab

- → Sample type/tube type
- → Preanalytical handling
- → Sample withdrawal

An example of how a biobank could be used

The Karma Intervention study – KARISMA-2


# The Karma Intervention Study – KARISMA-2

KARISMA 2

10

Delstudie:

- A dose determination trail five doses of tamoxifen and placebo
- Double blinded randomised controlled trial including 1,440 women



Eriksson, J Clinical Oncology, 2021

# The Karma Intervention Study – **KARISMA-2**

Delstudie:
KARISMA 2

11

We wanted to study germline DNA (e.g. CYP2D6 polymorphism), tamoxifen (and metabolites) concentrations, safety measures (liver tests, etc), protein and hormone levels, receptor expression, etc, in tissue

Tissue

•	Polymorphisms -	DNA
•	Safety -	Plasma
•	Metabolites of tamoxifen -	Plasma
•	Proteins -	Plasma
•	Hormones -	Plasma

D = 1, ... = = ... | = : = ... =

Receptors -

# KI Biobank, services

- Sample services
  - → Planning studies
  - → Ethics & regulatory advice
  - → Referrals & registration
  - → Blood sampling
  - → Sample preparations
  - → DNA extraction
  - → Sample withdrawal
- Data services
  - → Informed consent
  - → Lab info management (LIMS)
  - Data withdrawal
  - → Participant data (CRM/CRF)
  - → Data visualisation & access
  - → Survey data




Delstudie:

12

# KI Biobank, services

- Sample services
  - → Planning studies
  - → Ethics & regulatory advice
  - → Referrals & registration
  - → Blood sampling
  - → Sample preparations
  - → DNA extraction
  - → Sample withdrawal
- Data services
  - → Informed consent
  - → Lab info management (LIMS)
  - Data withdrawal
  - → Participant data (CRM/CRF)
  - → Data visualisation & access
  - → Survey data



Delstudie:

13




#### Informed consent

- ID
- Signature
  - → Participant
  - → Investigator
- Date and time

Delstudie: KARISMA 2

14

29 maj 2023 Karolinska Institutet



### Referral

Delstudie: KARISMA 2

15

- · ID
- Time point
- Sample type
- Tube type
- Bar code for tubes

# Summary









Inclusion





MTA DTA/DPA Collaboration agreement















16

Biobank Biobank Karisma-2 Karisma-2

Karolinska Biobank - tomorrow

# How could Principal Investigators and external researchers get access to information?

- How could information be transferred to researchers without the involvement of the biobank?
- How could transparency be increased?
- How could samples be better used?


Karolinska Institutet 29 maj 2023

# Sample withdrawals



Karolinska Institutet 29 maj 2023

## Sample withdrawals




**KIVIS** gives study specific information for researchers *regarding their own samples*:

- No. of participants, ID numbers
- No. and type of samples, date of sampling
- DNA concentrations, position in freezer, etc
- Status in LIMS (e.g. received, delivered)
- Possibility to add information such as diagnosis, medications, hospitalisation, etc, from registers


20

#### Karolinska Biobank Sample Collection Catalogue, beta version




Karolinska Institutet 29 maj 2023

#### Karolinska Biobank Sample Collection Catalogue, beta version




Karolinska Institutet 29 maj 2023

#### Karolinska Biobank Sample Collection Catalogue, , beta version



Karolinska Institutet 29 maj 2023

#### Karolinska Biobank Sample Collection Catalogue – The Karma Cohort



≈ 1.6 million aliquots

- 70,877 women
- Aliquots for each participant;
  - 1 DNA
  - 16 plasma
  - 2 whole blood back up
- Continuously matched to the Cause of Death-, Cancer-,
   In/Out patient-, Prescription-, MultiGeneration-, Emigration
   Registers

24

- ≈ 2,400 women diagnosed with breast cancer
- Collected 2010-2013
- (≈ 1.4 million mammograms)

#### Karolinska Biobank Sample Collection Catalogue

- A biobank is much more than a freezer
  - Karolinska Biobank is a core facility supporting scientists in questions regarding regulatory, legal, ethical, IT, data and laboratory issues
- KIVIS is a PI support system for getting detailed information about samples
- Karolinska Biobank Sample Collection Catalogue
  - is a meta data base for anyone to use
  - does not give any details of participants but a possibility to brows the content of the Karolinska Biobank
  - access has to be permitted by the study PIs

Karolinska Institutet 29 maj 2023

#### Karolinska Biobank – my own view

- Without Karolinska Biobank we would not have 1.6 million aliquots of plasma and DNA for ≈ 75,000 women
- We would not be able to collaborate with a large number of groups globally
- From a biobank / laboratory / sample preparation perspective, our trials are comparatively easy to conduct
- Cost is the draw back
  - Possible solution is to expand consent and open up more than today

Karolinska Institutet 29 maj 2023



**THANK YOU!**